A comprehensive approach to therapy of haematological malignancies in older patients

Sant, 2010, Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project, Blood, 116, 3724, 10.1182/blood-2010-05-282632 Krok-Schoen, 2018, Incidence and survival of hematological cancers among adults ages ≥75 years, Cancer Med, 7, 3425, 10.1002/cam4.1461 Mohile, 2018, Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology, J Clin Oncol, 36, 2326, 10.1200/JCO.2018.78.8687 Abel, 2018, Frailty and the management of hematologic malignancies, Blood, 131, 515, 10.1182/blood-2017-09-746420 Scheepers, 2020, Geriatric assessment in older patients with a hematologic malignancy: a systematic review, Haematologica, 105, 1484, 10.3324/haematol.2019.245803 Soto-Perez-de-Celis, 2021, Implementation of geriatric haematology programmes for the treatment of older people with haematological malignancies in low-resource settings, Lancet Healthy Longev, 10.1016/S2666-7568(21)00182-3 Cannella, 2018, How should we assess patient-reported outcomes in the onco-hematology clinic?, Curr Opin Support Palliat Care, 12, 522, 10.1097/SPC.0000000000000386 Soubeyran, 2019, Approaches for vulnerable and frail older patients with diffuse large B-cell lymphomas, Curr Opin Oncol, 31, 369, 10.1097/CCO.0000000000000559 Tucci, 2015, Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL), Leuk Lymphoma, 56, 921, 10.3109/10428194.2014.953142 Merli, 2021, Simplified geriatric assessment in older patients with diffuse large b-cell lymphoma: the prospective elderly project of the Fondazione Italiana Linfomi, J Clin Oncol, 39, 1214, 10.1200/JCO.20.02465 Saffore, 2019, Treatment of older patients with diffuse large B-cell lymphoma and mild cognitive impairment or dementia, J Geriatr Oncol, 10, 510, 10.1016/j.jgo.2018.09.002 Pfreundschuh, 2010, How I treat elderly patients with diffuse large B-cell lymphoma, Blood, 116, 5103, 10.1182/blood-2010-07-259333 Taplitz, 2018, Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update, J Clin Oncol, 36, 1443, 10.1200/JCO.2017.77.6211 Bartlett, 2020, Approaches to aggressive B-cell lymphomas in less fit patients, Hematology (Am Soc Hematol Educ Program), 2020, 140, 10.1182/hematology.2020000099 Eyre, 2021, Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP, Blood Adv, 5, 2229, 10.1182/bloodadvances.2021004286 Booth, 2020, Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma, Blood Adv, 4, 4337, 10.1182/bloodadvances.2020002553 Westin, 2013, Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial, Clin Lymphoma Myeloma Leuk, 13, 99, 10.1016/j.clml.2012.11.002 Peyrade, 2011, Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial, Lancet Oncol, 12, 460, 10.1016/S1470-2045(11)70069-9 Peyrade, 2017, Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group, Lancet Haematol, 4, e46, 10.1016/S2352-3026(16)30171-5 Pfreundschuh, 2004, Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL, Blood, 104, 634, 10.1182/blood-2003-06-2095 Oberic, 2021, Subcutaneous rituximab-miniCHOP compared with subcutaneous rituximab-miniCHOP plus lenalidomide in diffuse large b-cell lymphoma for patients age 80 years or older, J Clin Oncol, 39, 1203, 10.1200/JCO.20.02666 Fields, 2014, De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial, J Clin Oncol, 32, 282, 10.1200/JCO.2013.49.7586 Storti, 2018, Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi, Haematologica, 103, 1345, 10.3324/haematol.2017.186569 Luminari, 2018, Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi, Hematol Oncol, 36, 68, 10.1002/hon.2425 Eyre, 2019, Impact of intended and relative dose intensity of R-CHOP in a large, consecutive cohort of elderly diffuse large B-cell lymphoma patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by age, J Intern Med, 285, 681, 10.1111/joim.12889 Bataillard, 2021, Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review, Blood Adv, 5, 2426, 10.1182/bloodadvances.2021004665 Moccia, 2021, Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines, Blood Adv, 5, 1483, 10.1182/bloodadvances.2020002982 Eyre, 2019, Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity, Br J Haematol, 187, 185, 10.1111/bjh.16070 Cabannes-Hamy, 2018, Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies, Cancer Med, 7, 539, 10.1002/cam4.1139 Sehn, 2020, Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma, J Clin Oncol, 38, 155, 10.1200/JCO.19.00172 Salles, 2020, Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study, Lancet Oncol, 21, 978, 10.1016/S1470-2045(20)30225-4 Lin, 2021, Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma, Haematologica, 106, 255, 10.3324/haematol.2019.243246 Nastoupil, 2020, Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium, J Clin Oncol, 38, 3119, 10.1200/JCO.19.02104 Eichhorst, 2016, First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial, Lancet Oncol, 17, 928, 10.1016/S1470-2045(16)30051-1 Goede, 2014, Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions, N Engl J Med, 370, 1101, 10.1056/NEJMoa1313984 Hallek, 2010, Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial, Lancet, 376, 1164, 10.1016/S0140-6736(10)61381-5 Moreno, 2019, Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial, Lancet Oncol, 20, 43, 10.1016/S1470-2045(18)30788-5 Sharman, 2020, Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial, Lancet, 395, 1278, 10.1016/S0140-6736(20)30262-2 Goede, 2016, Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: results of the CLL9 trial of the German CLL study group, Leuk Lymphoma, 57, 789, 10.3109/10428194.2015.1091933 Molica, 2019, A simple score based on geriatric assessment predicts survival in elderly newly diagnosed chronic lymphocytic leukemia patients, Leuk Lymphoma, 60, 845, 10.1080/10428194.2018.1508674 Bonanad, 2015, Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale, J Geriatr Oncol, 6, 353, 10.1016/j.jgo.2015.03.003 Eichhorst, 2009, First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia, Blood, 114, 3382, 10.1182/blood-2009-02-206185 Hillmen, 2015, Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial, Lancet, 385, 1873, 10.1016/S0140-6736(15)60027-7 Michallet, 2018, Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study, Haematologica, 103, 698, 10.3324/haematol.2017.170480 Burger, 2015, Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia, N Engl J Med, 373, 2425, 10.1056/NEJMoa1509388 Woyach, 2018, Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL, N Engl J Med, 379, 2517, 10.1056/NEJMoa1812836 Fischer, 2019, Venetoclax and obinutuzumab in patients with CLL and coexisting conditions, N Engl J Med, 380, 2225, 10.1056/NEJMoa1815281 Furman, 2014, Idelalisib and rituximab in relapsed chronic lymphocytic leukemia, N Engl J Med, 370, 997, 10.1056/NEJMoa1315226 Al-Sawaf, 2018, Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia, Br J Haematol, 183, 727, 10.1111/bjh.15604 Eyre, 2020, The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia, Br J Haematol, 188, 918, 10.1111/bjh.16271 Sekeres, 2020, American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults, Blood Adv, 4, 3528, 10.1182/bloodadvances.2020001920 Borlenghi, 2021, Validation of the “fitness criteria” for the treatment of older patients with acute myeloid leukemia: a multicenter study on a series of 699 patients by the Network Rete Ematologica Lombarda (REL), J Geriatr Oncol, 12, 550, 10.1016/j.jgo.2020.10.004 Sorror, 2019, Revised acute myeloid leukemia composite model using the 2017 European LeukemiaNet Risk Classification, JAMA Oncol, 5, 1062, 10.1001/jamaoncol.2019.0902 Klepin, 2013, Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia, Blood, 121, 4287, 10.1182/blood-2012-12-471680 DiNardo, 2018, Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML, N Engl J Med, 378, 2386, 10.1056/NEJMoa1716984 Klepin, 2016, Effect of intensive chemotherapy on physical, cognitive, and emotional health of older adults with acute myeloid leukemia, J Am Geriatr Soc, 64, 1988, 10.1111/jgs.14301 Saad, 2020, Geriatric assessment and survival among older adults receiving postremission therapy for acute myeloid leukemia, Blood, 136, 2715, 10.1182/blood.2020005498 Lancet, 2018, CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia, J Clin Oncol, 36, 2684, 10.1200/JCO.2017.77.6112 DiNardo, 2020, Azacitidine and venetoclax in previously untreated acute myeloid leukemia, N Engl J Med, 383, 617, 10.1056/NEJMoa2012971 Wei, 2020, Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial, Blood, 135, 2137, 10.1182/blood.2020004856 Cortes, 2019, Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome, Leukemia, 33, 379, 10.1038/s41375-018-0312-9 Stein, 2017, Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia, Blood, 130, 722, 10.1182/blood-2017-04-779405 Wei, 2020, Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission, N Engl J Med, 383, 2526, 10.1056/NEJMoa2004444 Stone, 2017, Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation, N Engl J Med, 377, 454, 10.1056/NEJMoa1614359 Jones, 2021, Survival trends in elderly myeloma patients, Eur J Haematol, 106, 126, 10.1111/ejh.13530 Facon, 2018, Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma, Blood, 131, 301, 10.1182/blood-2017-07-795047 Mateos, 2018, Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma, N Engl J Med, 378, 518, 10.1056/NEJMoa1714678 Durie, 2017, Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial, Lancet, 389, 519, 10.1016/S0140-6736(16)31594-X Facon, 2019, Daratumumab plus lenalidomide and dexamethasone for untreated myeloma, N Engl J Med, 380, 2104, 10.1056/NEJMoa1817249 Larocca, 2021, Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma, Blood, 137, 3027, 10.1182/blood.2020009507 Giri, 2020, Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: a systematic review and meta-analysis, J Geriatr Oncol, 11, 1285, 10.1016/j.jgo.2020.05.013 Palumbo, 2015, Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report, Blood, 125, 2068, 10.1182/blood-2014-12-615187 Hshieh, 2018, Prevalence of cognitive impairment and association with survival among older patients with hematologic cancers, JAMA Oncol, 4, 686, 10.1001/jamaoncol.2017.5674 Larocca, 2021, Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma, Blood, 137, 3027, 10.1182/blood.2020009507 Cairns, 2019, Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (FiTNEss): a UK myeloma research alliance study, Myeloma XIV, Blood, 134 Nakaya, 2017, Realistic lenalidomide dose adjustment strategy for transplant-ineligible elderly patients with relapsed/refractory multiple myeloma: Japanese real-world experience, Acta Haematol, 138, 55, 10.1159/000477792 Facon, 2020, Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma, Blood Adv, 4, 5449, 10.1182/bloodadvances.2020001965 Extermann, 2021, Priorities for the global advancement of care for older adults with cancer: an update of the International Society of Geriatric Oncology Priorities Initiative, Lancet Oncol, 22, e29, 10.1016/S1470-2045(20)30473-3